Some Companies Say 'No' To China's Latest VBP Round
Branded Growth Without Price Cuts Still Possible
Only three of 40 qualified international drug firms won in the latest round of China's central bidding process, showing a toughening environment. But some companies are seemingly determined not to lower prices any further.
You may also be interested in...
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.
China’s latest volume-based purchase round is also the largest ever, covering more drugs and many of them are the widest-prescribed products. Novartis feels the pinch of price pressures but emphasizes a shift to new product launches.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.